November 30, 2023 — For the last two days, we have been both observing and participating in an NIH meeting on pharmacotherapy for obesity in children and youth that has been quite a pleasant surprise. Scientists, clinicians, parents, and young persons came together in a stimulating exchange of ideas. Perhaps the most notable dialogue focused on a desire to […]
July 2, 2022 — Nonalcoholic steatohepatitis – NASH – has yet again handed drug researchers disappointing results, this time in a study of semaglutide. Researchers presented this phase 2 study at the International Liver Congress in London last weekend. The whole point of a phase 2 study is to see if a drug works for a specific purpose. On […]
June 5, 2022 — This is what you might call a clean sweep. At the Scientific Sessions of the ADA and in NEJM yesterday, researchers unveiled detailed data on tirzepatide for obesity. When Lilly gave us a peek at these data a month ago, “Wow!” was our response. With the full details in view and peer reviewed, we tend […]
February 24, 2022 — “Bariatric surgery may be a powerful tool in breast cancer prevention and treatment,” write Trevor Crafts and colleagues in a new review paper for Obesity. But there’s just one problem. All of the research that points to this possible value is observational. So we need a prospective clinical trial of bariatric surgery to reduce the […]
November 20, 2021 — Lancet this week published the biggest study yet of cagrilintide – evidence that we’re seeing success in progress with more options for anti-obesity medicines. In a commentary alongside this study, Kishore Gadde and David Allison call this promising news. They point to the advantage of having a new mechanism of action for treating obesity. Also, […]
May 8, 2021 — It’s 2021 and the medical world has mostly moved on from the archaic view of bariatric surgery as a treatment of last resort for obesity. For many patients, delaying bariatric surgery harms their health. The rest of the world is still struggling to catch up. But healthcare providers who care for people living with obesity […]
June 9, 2019 — Some of the most discussed news coming from the American Diabetes Association Scientific Sessions in San Francisco is all about the PIONEER studies of oral semaglutide. This drug is presently under review at FDA for type 2 diabetes. Interest is keen because it will be the first of its class that doesn’t require an injection. […]
